Cargando…

Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers

Real-world evidence surrounding EGFR positive NSCLC patients in Canada is limited. Administrative databases in Alberta, Canada were used to evaluate EGFR testing and mutation prevalence in de novo metastatic NSCLC, as well as the characteristics, treatment patterns, and outcomes of individuals with...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Sullivan, Dylan E., Jarada, Tamer N., Yusuf, Amman, Hu, Leo (Xun Yang), Gogna, Priyanka, Brenner, Darren R., Abbie, Erica, Rose, Jennifer B., Eaton, Kiefer, Elia-Pacitti, Julia, Ewara, Emmanuel M., Pabani, Aliyah, Cheung, Winson Y., Boyne, Devon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600059/
https://www.ncbi.nlm.nih.gov/pubmed/36290844
http://dx.doi.org/10.3390/curroncol29100567
_version_ 1784816747271946240
author O’Sullivan, Dylan E.
Jarada, Tamer N.
Yusuf, Amman
Hu, Leo (Xun Yang)
Gogna, Priyanka
Brenner, Darren R.
Abbie, Erica
Rose, Jennifer B.
Eaton, Kiefer
Elia-Pacitti, Julia
Ewara, Emmanuel M.
Pabani, Aliyah
Cheung, Winson Y.
Boyne, Devon J.
author_facet O’Sullivan, Dylan E.
Jarada, Tamer N.
Yusuf, Amman
Hu, Leo (Xun Yang)
Gogna, Priyanka
Brenner, Darren R.
Abbie, Erica
Rose, Jennifer B.
Eaton, Kiefer
Elia-Pacitti, Julia
Ewara, Emmanuel M.
Pabani, Aliyah
Cheung, Winson Y.
Boyne, Devon J.
author_sort O’Sullivan, Dylan E.
collection PubMed
description Real-world evidence surrounding EGFR positive NSCLC patients in Canada is limited. Administrative databases in Alberta, Canada were used to evaluate EGFR testing and mutation prevalence in de novo metastatic NSCLC, as well as the characteristics, treatment patterns, and outcomes of individuals with Exon 19, L858R and Exon20ins mutations. Between 2013–2019, 2974 individuals underwent EGFR testing, of which 451 (15.2%) were EGFR positive. Among EGFR positive individuals, 221 (49.0%) had an Exon 19 mutation, 159 (35.3%) had an L858R mutation, and 18 (4%) had an Exon20ins mutation. The proportion of individuals who initiated 1L systemic therapy was 89.1% for Exon19, 85.5% for L858R, and 72.2% for Exon20ins carriers. The primary front-line systemic therapy was gefitinib or afatinib monotherapy for individuals with Exon 19 (93.4%) and L858R (94.1%) mutations versus platinum combination therapy for individuals with Exon20ins mutations (61.5%). The Exon20ins cohort had worse median overall survival from initiation of 1L systemic therapy (10.5 months [95% CI: 8.0-not estimable]) than the Exon19 (20.6 months [95% CI: 18.4–24.9]), and L858R cohorts (19.1 months [95% CI: 14.5–23.1]). These findings highlight that Exon20ins mutations represent a rare subset of NSCLC in which treatment options are limited and survival outcomes are worse relative to individuals with more common types of EGFR mutations.
format Online
Article
Text
id pubmed-9600059
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96000592022-10-27 Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers O’Sullivan, Dylan E. Jarada, Tamer N. Yusuf, Amman Hu, Leo (Xun Yang) Gogna, Priyanka Brenner, Darren R. Abbie, Erica Rose, Jennifer B. Eaton, Kiefer Elia-Pacitti, Julia Ewara, Emmanuel M. Pabani, Aliyah Cheung, Winson Y. Boyne, Devon J. Curr Oncol Article Real-world evidence surrounding EGFR positive NSCLC patients in Canada is limited. Administrative databases in Alberta, Canada were used to evaluate EGFR testing and mutation prevalence in de novo metastatic NSCLC, as well as the characteristics, treatment patterns, and outcomes of individuals with Exon 19, L858R and Exon20ins mutations. Between 2013–2019, 2974 individuals underwent EGFR testing, of which 451 (15.2%) were EGFR positive. Among EGFR positive individuals, 221 (49.0%) had an Exon 19 mutation, 159 (35.3%) had an L858R mutation, and 18 (4%) had an Exon20ins mutation. The proportion of individuals who initiated 1L systemic therapy was 89.1% for Exon19, 85.5% for L858R, and 72.2% for Exon20ins carriers. The primary front-line systemic therapy was gefitinib or afatinib monotherapy for individuals with Exon 19 (93.4%) and L858R (94.1%) mutations versus platinum combination therapy for individuals with Exon20ins mutations (61.5%). The Exon20ins cohort had worse median overall survival from initiation of 1L systemic therapy (10.5 months [95% CI: 8.0-not estimable]) than the Exon19 (20.6 months [95% CI: 18.4–24.9]), and L858R cohorts (19.1 months [95% CI: 14.5–23.1]). These findings highlight that Exon20ins mutations represent a rare subset of NSCLC in which treatment options are limited and survival outcomes are worse relative to individuals with more common types of EGFR mutations. MDPI 2022-09-30 /pmc/articles/PMC9600059/ /pubmed/36290844 http://dx.doi.org/10.3390/curroncol29100567 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
O’Sullivan, Dylan E.
Jarada, Tamer N.
Yusuf, Amman
Hu, Leo (Xun Yang)
Gogna, Priyanka
Brenner, Darren R.
Abbie, Erica
Rose, Jennifer B.
Eaton, Kiefer
Elia-Pacitti, Julia
Ewara, Emmanuel M.
Pabani, Aliyah
Cheung, Winson Y.
Boyne, Devon J.
Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers
title Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers
title_full Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers
title_fullStr Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers
title_full_unstemmed Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers
title_short Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers
title_sort prevalence, treatment patterns, and outcomes of individuals with egfr positive metastatic non-small cell lung cancer in a canadian real-world setting: a comparison of exon 19 deletion, l858r, and exon 20 insertion egfr mutation carriers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600059/
https://www.ncbi.nlm.nih.gov/pubmed/36290844
http://dx.doi.org/10.3390/curroncol29100567
work_keys_str_mv AT osullivandylane prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers
AT jaradatamern prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers
AT yusufamman prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers
AT huleoxunyang prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers
AT gognapriyanka prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers
AT brennerdarrenr prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers
AT abbieerica prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers
AT rosejenniferb prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers
AT eatonkiefer prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers
AT eliapacittijulia prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers
AT ewaraemmanuelm prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers
AT pabanialiyah prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers
AT cheungwinsony prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers
AT boynedevonj prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers